<DOC>
	<DOCNO>NCT02609945</DOCNO>
	<brief_summary>This study first study human CVT-427 ( zolmitriptan inhalation powder ) design evaluate safety , tolerability , PK single ascend dos CVT-427 adult healthy volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetics ( PK ) Study Single Ascending Doses CVT-427 ( Zolmitriptan Inhalation Powder ) In Healthy Adults</brief_title>
	<detailed_description>Objectives : - To evaluate overall safety tolerability single , inhaled dos CVT-427 ( zolmitriptan inhalation powder ) healthy adult , special emphasis cardiopulmonary effect . - To describe pharmacokinetics ( PK ) single , inhaled dos CVT-427 , Zomig® Tablet , Zomig® Nasal Spray healthy adult .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Healthy adult men woman volunteer age 18 65 year , inclusive ; Triptannaïve ; Body mass index ( BMI ) 18 30 kg/m2 ; Forced expiratory volume one second ( FEV1 ) great 80 % predict race , age , sex , height FEV1/FVC ( force vital capacity ) ratio great equal 70 % ; No history asthma ; Nonsmoking least 5 year ; In good general health clinically significant abnormality recognize cardiovascular risk factor preclude use triptans would interfere participation study determine medical history , physical examination , electrocardiogram , clinical laboratory test result ; negative test drug alcohol , serology , pregnancy female subject childbearing potential . Subject surgically sterile female subject le 2 year postmenopausal , agree use highly effective birth control method study 3 month last dose investigational product ; Any cardiovascular risk factor include clinically relevant ECG parameter ( e.g. , PR interval , QRS deviation ) clinically significant ECG abnormality ; History asthma ( include exerciseinduced asthma coldinduced asthma ) chronic obstructive pulmonary disorder ( COPD ) require intermittent continuous use oral inhaled medication therapy within last 3 year ; Any flulike syndrome respiratory infection within 4 week CVT427 administration ; Unable tolerate blood draw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Migraine attack</keyword>
</DOC>